http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Application of a wireless pressure sensing system to coastal wind monitoring
Pinelli, J.P.,Subramanian, C.S.,Lapilli, C.,Buist, L. Techno-Press 2005 Wind and Structures, An International Journal (WAS Vol.8 No.3
This paper describes the application of a wireless data acquisition system to monitor wind pressures and velocities with absolute pressure sensors and an anemometer. The system was developed for future deployment, as part of a research effort currently underway to instrument coastal homes in Florida to monitor roof wind pressures during hurricanes. The proposed wireless system will replace the current system that involves a large amount of hardwired connections from the sensors to the data processing unit that requires labor intensive wiring and preparation of the home. The paper describes comparison studies and field tests to assess the performance of the system. The new system offers the advantages of light hardware, ease of installation, capacity for 48 hours of continuous data acquisition, good frequency and amplitude responses, and a relatively simple maintenance. However, the tests also show that the shape of the shell that has been previously used to protect the sensors might interfere with the proper measurement of the pressures.
Rachel F. Madera,Lihua Wang,Wenjie Gong,Yulia Burakova,Sterling Buist,Jerome Nietfeld,Jamie Henningson,Ada G. Cino-Ozuna,Changchun Tu,Jishu Shi 대한수의학회 2018 JOURNAL OF VETERINARY SCIENCE Vol.19 No.3
Highly contagious classical swine fever (CSF) remains a major trade and health problem in the pig industry, resulting in large economic losses worldwide. In CSF-endemic countries, attenuated CSF virus (CSFV) vaccines have been routinely used to control the disease. However, eradication of CSFV in a geographical area would require permanent reduction to zero presence of the virus. It is therefore of paramount importance to develop a safe, potent, and non-infectious CSF vaccine. We have previously reported on a cost-effective CSF E2 subunit vaccine, KNB-E2, which can protect against CSF symptoms in a single dose containing 75 mg of recombinant CSFV glycoprotein E2. In this study, we report on a series of animal studies undertaken to elucidate further the efficacy of KNB-E2. We found that pigs vaccinated with a single KNB-E2 dose containing 25 mg of recombinant CSFV glycoprotein E2 were protected from clinical symptoms of CSF. In addition, KNB-E2-mediated reduction of CSF symptoms was observed at two weeks post-vaccination and the vaccinated pigs continued to exhibit reduced CSF clinical signs when virus challenged at two months and four months post-vaccination. These results suggest that KNB-E2 effectively reduces CSF clinical signs, indicating the potential of this vaccine for safely minimizing CSF-related losses.